Core‐shell model drug carriers on two nanoscale size levels have been applied in cell culture studies and focused on Toxoplasmosis therapy. In synthesis, a seed of rhodamin B‐labelled polystyrene latex particles was coated by polybutyl cyanoacrylate under physical inclusion of two different new drugs against Toxoplasmosis. Drug‐loaded and drug‐free core‐shell model drug carriers were added to a cell culture of human macrophages, infected by Toxoplasma gondii, following an infection plan. Drug release from the carriers had been studied before by enzymatic degradation by means of pork liver esterase. Particle size decrease by degradation was investigated in a UV/VIS spectrometer via transmission measurements. Drug release profiles were obtained by HPLC studies. The dynamics in the population of infected human macrophages, T. gondii as well as model drug carrier numbers were registered by an FACS (fluorescence‐activated cell sorter). As main result, the drug‐free references in the two series of core‐shell model drug carriers achieved ca.85% of the observed maximum in Toxoplasmosis therapy efficiency. These data were correlated with an immune stimulant effect on the side of the human macrophages, caused by the cell uptake of colloidal substrate, foreign to the body.
Part of the book: Toxoplasmosis